Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Wander P, Cheung LC, Pinhanҫos SS, Jones L, Kerstjens M, Arentsen-Peters STCJM, Singh S, Chua GA, Castro PG, Schneider P, Dolman MEM, Koopmans B, Molenaar JJ, Pieters R, Zwaan CM, Kotecha RS, Stam RW. Wander P, et al. Among authors: kerstjens m. Leukemia. 2020 Nov;34(11):2898-2902. doi: 10.1038/s41375-020-0895-9. Epub 2020 Jun 2. Leukemia. 2020. PMID: 32488115 No abstract available.
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L, Bate-Eya LT, Alles LK, Lee JY, Koopmans B, Jonus HC, Schubert NA, Schild L, Lelieveld D, Egan DA, Kerstjens M, Stam RW, Koster J, Goldsmith KC, Molenaar JJ, Dolman MEM. Vernooij L, et al. Among authors: kerstjens m. Mol Cancer Ther. 2021 Jun;20(6):1161-1172. doi: 10.1158/1535-7163.MCT-20-0666. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850004 Free PMC article.
High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.
Wander P, Arentsen-Peters STCJM, Vrenken KS, Pinhanҫos SM, Koopmans B, Dolman MEM, Jones L, Garrido Castro P, Schneider P, Kerstjens M, Molenaar JJ, Pieters R, Zwaan CM, Stam RW. Wander P, et al. Among authors: kerstjens m. Biomedicines. 2022 Mar 10;10(3):638. doi: 10.3390/biomedicines10030638. Biomedicines. 2022. PMID: 35327440 Free PMC article.
Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL.
Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, Garrido Castro P, Fazio G, Van Roon EHJ, Kerstjens M, Smithers N, Prinjha RK, Te Kronnie G, Basso G, Stam RW, Pieters R, Biondi A, Cazzaniga G. Bardini M, et al. Among authors: kerstjens m. Mol Cancer Ther. 2018 Aug;17(8):1705-1716. doi: 10.1158/1535-7163.MCT-17-1123. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748211